CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis

The Journal of Pathology
R RistamäkiS Jalkanen

Abstract

The family of CD44 glycoproteins has diverse functions in cell-cell and cell-matrix interactions. The standard form of CD44 is of importance in the dissemination of lymphoma, whereas the clinical significance of the variant exon v6-containing forms of CD44 (CD44v6) is not known. The expression of different forms of CD44 was investigated by using antibodies against the constant part of CD44 (CD44c) and CD44v6 in 56 primary and 17 recurrent non-Hodgkin's lymphomas and correlated with several clinicopathological parameters and with prognosis. Fifty-seven per cent of the primary non-Hodgkin's lymphomas expressed CD44v6 and 73 per cent expressed the constant epitope. Expression of both CD44c and CD44v6 was associated with low histological grade of malignancy. CD44c expression was associated with a low cellular proliferation rate as assessed by DNA flow cytometry. Of several factors tested, high expression of the variant from v6 was the only factor that was associated with unfavourable recurrence-free survival (P = 0.04). We conclude that CD44v6 is associated with a low histological grade, but, on the other hand, with an unfavourable outcome, which suggests that the combination of CD44v6 and histological grading may form a particular...Continue Reading

References

Feb 20, 1992·International Journal of Cancer. Journal International Du Cancer·M C KuppnerN de Tribolet
May 1, 1991·The Journal of Clinical Investigation·S JalkanenP Klemi
Jul 1, 1990·The Journal of Experimental Medicine·K MiyakeP W Kincade
Feb 1, 1990·The Journal of Experimental Medicine·K MiyakeP W Kincade
Dec 1, 1989·Immunology Today·B F HaynesS M Denning
Feb 6, 1988·Lancet·A G StansfeldO Mioduszewska
Jan 1, 1988·Immunogenetics·M B OmaryC M Isacke
Jan 1, 1986·Current Topics in Microbiology and Immunology·E C Butcher
Nov 1, 1984·The Journal of Cell Biology·K JacobsonJ T August
Nov 1, 1983·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·D W HedleyE A Musgrove
Oct 23, 1993·Lancet·B MayerJ P Johnson
Aug 28, 1993·Lancet·S B FoxJ Fawcett

❮ Previous
Next ❯

Citations

Apr 22, 1997·International Journal of Cancer. Journal International Du Cancer·P SpeiserC Kainz
May 8, 2002·Pathology Oncology Research : POR·Elif AkisikNejat Dalay
Jan 25, 2011·Annals of Hematology·Magdalena Katharina HertweckKarl-Anton Kreuzer
Apr 25, 2003·Critical Reviews in Oncology/hematology·Tracey A MartinWen G Jiang
Oct 19, 1999·Journal of Pediatric Hematology/oncology·M TakeuchiM Mayumi
May 29, 1998·Journal of Clinical Pathology·E M CastellàI Ojanguren
May 21, 2016·Stem Cells International·Ranjeeta Thapa, George D Wilson
Jul 3, 1999·Japanese Journal of Cancer Research : Gann·S SatoE Tahara
Jul 1, 1997·Human Pathology·J S LyzakL Joseph
Jul 27, 2001·Pediatrics International : Official Journal of the Japan Pediatric Society·N TaçyildizS Cin
Dec 18, 2002·Critical Reviews in Clinical Laboratory Sciences·David NaorYoram Faitelson
May 26, 1998·Japanese Journal of Cancer Research : Gann·Y TokueT Kakizoe
Oct 26, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·F Anwar, B L Wood
Feb 19, 1999·Journal of Clinical Pathology·J A IrvingA R Cattan
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Leslie K DiazMichael Z Gilcrease
Sep 18, 1998·The Journal of Investigative Dermatology·S N WagnerM Goos
Jul 7, 2005·Clinical Oncology : a Journal of the Royal College of Radiologists·W MaL Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.